Moderna publishes Analyst Day transcript
MRNA•Moderna expects to invest about $4 billion in 2027, up from $3.8 billion in 2026, primarily due to increased spending on intismeran. The company projects annual investment of $4 billion-$4.5 billion afterward and says intismeran could launch in 2027, subject to regulatory approval.
1. Investment plans
Management expects investment of about $4 billion in 2027, compared with $3.8 billion in 2026, primarily reflecting increased spending on intismeran. Annual investment is subsequently projected at $4 billion-$4.5 billion, with additional spending dependent on pipeline results.
2. Intismeran and vaccines
Intismeran could launch in 2027, subject to regulatory approval. Its commercial manufacturing site is targeting approximately six weeks from sample collection to dosing. CFO James Mock cautioned against assuming recurring vaccine revenue growth of 15%-25%, the current 2026 forecast, despite expectations for further expansion.




